Is Midostaurin expensive? Can it be reimbursed?

Midostaurin is a new generation of acute myeloid leukemia (AML) targeted drug, its price varies greatly in different countries and markets. In China, the original drug Midostaurin has not yet been approved for marketing, so it has not yet been included in medical insurance, and the price information is still unclear. This means that it is difficult for patients to obtain original drugs through formal channels in China, and they need to rely on overseas imports or clinical trials.

In overseas markets, the original version of midostaurin is available in various versions, such as the European version, the Turkish version and the Indian version. The common packaging specification is 25mg*112 tablets. The price of each box may range from RMB 10,000 to RMB 70,000. The price is greatly affected by the exchange rate and supply channels. Because acute myeloid leukemia is a high-risk hematological malignant disease, long-term treatment is expensive and imposes a heavy financial burden on patients.

In order to reduce treatment costs, midostaurin generics have been launched in some overseas markets. For example, the generic drugs produced by India's BDR pharmaceutical factory have almost the same ingredients as the original drugs and are equally effective. The price is about RMB 3,000 per box, providing a more economical treatment option. Such generic drugs can provide patients with an affordable source of medicines, subject to formal registration and quality assurance.

Since midostaurin is not yet on the market in China, if patients want to obtain the drug, they need to obtain it through formal overseas channels or participate in clinical research projects. At the same time, they must ensure that the source of the drug is legal and safe, and avoid purchasing drugs through unknown channels to ensure drug safety and therapeutic effect.

Generally speaking, the price of midostaurin is relatively high, but the emergence of generic drugs provides patients with a feasible economic alternative. However, medical insurance policies have not yet covered it, and patients need to conduct a full economic and risk assessment before taking the drug.

Reference materials:https://go.drugbank.com/drugs/DB06595